Defining the Expectations of Your Center’s Leaders Cancer Center Administrators’ Forum April 2011
Dec 26, 2015
Defining the Expectationsof Your Center’s Leaders
Cancer Center Administrators’ ForumApril 2011
Cancer Center Leadership Roles
Cancer Center Director: this role is usually well defined both by the NCI CCSG guidelines and by the institution Vision/strategic planning - Budget Recruitment - Fundraising Equivalent to departmental chair - Space
Deputy Director, Associate Directors, Program Leaders and Shared Resource Directors Often times the authority, expectations and responsibilities
of these positions are ill defined
Today’s Presentations
Associate Director Role Anita Harrison, Hollings Cancer Center, MUSC Melanie Thomas, Associate Director of
Clinical Investigations
Program Leader Role Kimberly Kerstann, Winship Cancer Institute, Emory Paula Vertino, Cancer Genetics & Epigenetics
Program Leader
Shared Resource Director Role Stephen Long, Greenebaum Cancer Center, U of Maryland Nicholas Ambulos, Director of Shared Services
Associate Director
Common Cancer Center Associate Director Positions Basic Science - Prevention & Control Clinical Investigations - Cancer Disparities Translational Research - Administration Shared Resources - Clinical Affairs Education
Generally, these positions are considered the Center’s “Senior Leadership” and report to the Director or Deputy Director
Typically, they receive CCSG support for 10-20% effort; total Center support can be up to 50%
Meet 1-2 times a month as a group with Director/Deputy
Associate Directors
Formulate priorities, strategies and provide input into the allocation of resources
Closely monitor the strength of several of the CCSG Essential Characteristics (cancer focus, research facilities, inter/transdisciplinary interactions, organizational capabilities) across the Center
Evaluate Center’s progress in meeting strategic planning goals
Expected to be inter-connected with other departmental/college/campus-wide efforts to build synergy with the Cancer Center
Defining the Associate Director’s Role
Create a job description for each
Role should be distinct from other roles but clarify any areas of overlap and make sure that these are well articulated Associate Director (Breadth) vs Program Leader (Depth)
Define what financial resources they have to accomplish their job and/or what part of the Center’s budget are they accountable for
Effectiveness should be annually reviewed (peer review by other Associate Directors and Program Leaders; EAB)
Associate Director of Clinical Investigations
Melanie B. Thomas, MDAssociate Professor of Medicine
Grace E. DeWolff Chair in GI Oncology
Recruited in 2008 from University of Texas M.D. Anderson Cancer Center
Nationally-recognized for her multidisciplinary clinical research program in hepatobiliary cancer
2009 NCI Clinical Leadership Team Award
Cancer Center supports 30% effort for this role
Authorities and Responsibilities
Authorities and Responsibilities
Identify clinical research expertise needed and work with Director and institutional leaders (dept, divisions) to facilitate faculty recruitment
Integrate investigators into multidisciplinary groups in which they are actively engaged with basic and population based researchers in developing translational research
Cancer Genes & Molecular Regulation
Lipid Signaling in
Cancer
Developmental Cancer
Therapeutics
Cancer Immunology
HCC Research Programs
Clinical and Laboratory Interface
TRANSLATIONAL RESEARCH
H&N GUBreast Thoracic
Established Disease-based Research Groups with Key Clinical Faculty
Hem/Mal
BakerJenretteKramer
Christiansen
DayGillespie
ShiraiSharma
ReedDenlingerSilvestriSimon
KraftDrabkinKeane
Golshayan
StuartKraveka
HudspethCosta
Neuro
GiglioPatel
GI
ThomasEsnaola
ChinCamp
CancerPrevention& Control
Authorities and Responsibilities
Promotion of investigator initiated trials, especially with Center’s pre-clinical investigators
Develop consortium relationships with NCI Phase I and Phase II awardees as well as industry partners to develop and conduct novel trials
Promotion and facilitation of the development of leadership within cooperative groups
Increase clinical trial accrual; work with Associate Director of Cancer Disparities to promote minority participation
Strategies Employed
ExPERT – junior clinical investigators meet monthly with Dr. Thomas and invited shared resource directors and program leaders to discuss correlative science concepts
Pfizer 3D Program (Sept 2010)
Disease & Program Retreats 10 in 2010
Abney Clinical Scholars – HCC salary support for new junior faculty for protected time (Graybill, Young)
Ongoing faculty recruitment – 2010 HCC further investing in CTO to support accrual/protocol development (VA, East
Cooper, Phase I)
Shifting the Portfolio Toward IITs
IITs11%
Cooperative Group66%
Industry 20%
Other Peer Reviewed
3%
Other Peer Reviewed
2%Industry
24%
Cooperative Group
51%
IITs23%
HCC Active Therapeutic Studies by Sponsor
2008(N=122)
2011(N=126)
2 Active Phase I Trials in 2008 10 Active Phase I Trials in 2011
15 by 2015The Next Breakthrough Could Be Yours
• Less than 1% of adults in SC diagnosed with cancer enroll on a therapeutic clinical trial
• 254 patients (12.4% of new patients) enrolled onto a therapy trial at the HCC in 2010
• HCC led statewide public policy changes in 2010 to ensure every person with insurance has access to cancer clinical trials
• The HCC goal is to increase enrollment to therapy trials to 15% by 2015
• Goals: - Raise everyone's awareness of clinical trials
- Integrate clinical trials into all standard pt care practices
- Foster culture that values and promotes faculty/staff involvement in clinical trials
• Strategies: - Continual rounding with faculty/staff about clinical trials - Identify and knock down ALL barriers to enrolling - Visuals: banners (12), posters (80), buttons, info cards - Commitment by MUSC leadership to hold faculty/staff accountable for growth in clinical trials
15 by 2015The Next Breakthrough Could Be Yours
15 by 2015The Next Breakthrough Could Be Yours
HCC Therapeutic Accrual to Cancer Clinical Trials(assumes a 3% growth in overall pt volume/year)